U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C15H17NO2
Molecular Weight 243.3015
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AGOMELATINE

SMILES

CC(=NCCc1cccc2ccc(cc21)OC)O

InChI

InChIKey=YJYPHIXNFHFHND-UHFFFAOYSA-N
InChI=1S/C15H17NO2/c1-11(17)16-9-8-13-5-3-4-12-6-7-14(18-2)10-15(12)13/h3-7,10H,8-9H2,1-2H3,(H,16,17)

HIDE SMILES / InChI
Molecular Formula C15H17NO2
Molecular Weight 243.3015
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/12750432 | https://www.ncbi.nlm.nih.gov/pubmed/12764576 | http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000915/WC500046227.pdf

Agomelatine behaves both as a potent agonist at melatonin MT1 and MT2 receptors and as a neutral antagonist at 5-HT2C receptors. Accumulating evidence in a broad range of experimental procedures supports the notion that the psychotropic effects of agomelatine are due to the synergy between its melatonergic and 5-hydroxytryptaminergic effects. Agomelatine is indicated for the treatment of major depressive episodes.

CNS Activity

Originator

Approval Year

Unknown
109281
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2470
 0.1 nM [Ki]
Agonist
2470
 0.12 nM [Ki]
Antagonist
2575
 6.2 null [pKi]
Antagonist
2575
 6.6 null [pKi]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8043
VALDOXAN

Approved Use

Treatment of major depressive episodes.

Launch Date

1.23491516E12
PubMed

PubMed

TitleDatePubMed
Differential effects of the novel antidepressant agomelatine (S 20098) versus fluoxetine on 5-HT1A receptors in the rat brain.
2004 Sep
Newer treatment studies for bipolar depression.
2005
[Development of a new antidepressant : agomelatine].
2005 Oct
Anxiolytic-like action of the antidepressant agomelatine (S 20098) after a social defeat requires the integrity of the SCN.
2005 Oct
[Depression and neuroplasticity: implication of serotoninergic systems].
2005 Sep-Oct
Agomelatine: a preliminary review of a new antidepressant.
2006
New directions for drug discovery.
2006
Treatments in depression.
2006
Therapeutic potential of melatonin ligands.
2006
Effects of melatonin and agomelatine in anxiety-related procedures in rats: interaction with diazepam.
2006 Aug
Efficacy and tolerance profile of agomelatine and practical use in depressed patients.
2006 Feb
Sleep disturbances and depression: a challenge for antidepressants.
2006 Feb
Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety.
2006 Feb
Placebo-controlled trial of agomelatine in the treatment of major depressive disorder.
2006 Feb
Melatonin: Nature's most versatile biological signal?
2006 Jul
Prospects for the treatment of depression.
2006 May
[Agomelatine: the first "melatoninergic" antidepressant].
2006 Oct
New antidepressants or more of the same?
2007
Agomelatine and its therapeutic potential in the depressed patient.
2007 Aug
Emerging treatments for major depression.
2007 Feb
Agomelatine in the treatment of seasonal affective disorder.
2007 Mar
Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine.
2007 Nov
The interaction between the internal clock and antidepressant efficacy.
2007 Oct
Major depressive disorder, sleep EEG and agomelatine: an open-label study.
2007 Oct
[Pharmacotherapy of depression: recent developments].
2007 Sep 19
Effects of different antidepressant treatments on the core of depression.
2008
Core symptoms of major depressive disorder: relevance to diagnosis and treatment.
2008
Promising avenues of therapeutics for bipolar illness.
2008
Melatonin receptor agonists: SAR and applications to the treatment of sleep-wake disorders.
2008
Gateways to clinical trials.
2008 Apr
Agomelatine treatment of major depressive disorder.
2008 Dec
Agomelatine, a melatonin receptor agonist with 5-HT(2C) receptor antagonist properties, protects the developing murine white matter against excitotoxicity.
2008 Jun 24
Melatonin and its agonists: an update.
2008 Oct
Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study.
2008 Oct
Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data.
2008 Sep
Addressing circadian rhythm disturbances in depressed patients.
2008 Sep
Innovation translates into antidepressant effectiveness.
2008 Sep
Agomelatine, an innovative pharmacological response to unmet needs.
2008 Sep
Melatonin receptor agonist agomelatine: a new drug for treating unipolar depression.
2009
Insomnia in patients with depression: some pathophysiological and treatment considerations.
2009
Melatonin and melatonergic drugs on sleep: possible mechanisms of action.
2009
Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.
2009
The effect of melatonergic and non-melatonergic antidepressants on sleep: weighing the alternatives.
2009
The antidepressant agomelatine blocks the adverse effects of stress on memory and enables spatial learning to rapidly increase neural cell adhesion molecule (NCAM) expression in the hippocampus of rats.
2009 Apr
Pathophysiology of depression: role of sleep and the melatonergic system.
2009 Feb 28
Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep-wake cycle architecture.
2009 Jul
Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis.
2009 Jun
Agomelatine improves symptoms of generalised anxiety disorder.
2009 May
Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders.
2009 Winter
Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale.
2010 Jan
Patents

Patents

07183318
3
07498465
4
JP2005239718A
3
JP2007182440A
3
JP2009137943A
3
JP2010037345A
3
JP2010280699A
3

Sample Use Guides

In Vivo Use Guide
The recommended dose is 25 mg once daily taken orally at bedtime. After two weeks of treatment, if there is no improvement of symptoms, the dose may be increased to 50 mg once daily, i.e. two 25 mg tablets, taken together at bedtime. Decision of dose increase has to be balanced with a higher risk of transaminases elevation. Any dose increase to 50 mg should be made on an individual patient benefit/risk basis and with strict respect of LFT monitoring.
Route of Administration: Oral
In Vitro Use Guide
hypothalamic suprachiasmatic nucleus firing rates were dose-dependently suppressed by 19.2-80.9% following perfusion of 0.04-0.32mM agomelatine (p<0.001, IC50=0.14mM).
Substance Class Chemical
Created
by admin
on Fri Jun 25 22:17:30 UTC 2021
Edited
by admin
on Fri Jun 25 22:17:30 UTC 2021
Record UNII
137R1N49AD
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AGOMELATINE
EMA EPAR   INN   MART.   MI   WHO-DD  
INN  
Official Name English
AGOMELATINE [MI]
Common Name English
VALDOXAN
Brand Name English
S20098
Code English
THYMANAX
Brand Name English
AGOMELATINE [WHO-DD]
Common Name English
N-(2-(7-METHOXY-1-NAPHTHYL)ETHYL)ACETAMIDE
Systematic Name English
AGOMELATINE [EMA EPAR]
Common Name English
AGOMELATINE [INN]
Common Name English
AGOMELATINE [MART.]
Common Name English
S-20098
Code English
Classification Tree Code System Code
NCI_THESAURUS C66885
Created by admin on Fri Jun 25 22:17:30 UTC 2021 , Edited by admin on Fri Jun 25 22:17:30 UTC 2021
WHO-VATC QN06AX22
Created by admin on Fri Jun 25 22:17:30 UTC 2021 , Edited by admin on Fri Jun 25 22:17:30 UTC 2021
EMA ASSESSMENT REPORTS THYMANAX (AUTHORIZED: DEPRESSIVE DISORDER, MAJOR)
Created by admin on Fri Jun 25 22:17:30 UTC 2021 , Edited by admin on Fri Jun 25 22:17:30 UTC 2021
NCI_THESAURUS C28197
Created by admin on Fri Jun 25 22:17:30 UTC 2021 , Edited by admin on Fri Jun 25 22:17:30 UTC 2021
WHO-ATC N06AX22
Created by admin on Fri Jun 25 22:17:30 UTC 2021 , Edited by admin on Fri Jun 25 22:17:30 UTC 2021
EMA ASSESSMENT REPORTS VALDOXAN (REFUSED: DEPRESSIVE DISORDER, MAJOR)
Created by admin on Fri Jun 25 22:17:30 UTC 2021 , Edited by admin on Fri Jun 25 22:17:30 UTC 2021
Code System Code Type Description
NCI_THESAURUS
C72684
Created by admin on Fri Jun 25 22:17:30 UTC 2021 , Edited by admin on Fri Jun 25 22:17:30 UTC 2021
PRIMARY
DRUG CENTRAL
99
Created by admin on Fri Jun 25 22:17:30 UTC 2021 , Edited by admin on Fri Jun 25 22:17:30 UTC 2021
PRIMARY
FDA UNII
137R1N49AD
Created by admin on Fri Jun 25 22:17:30 UTC 2021 , Edited by admin on Fri Jun 25 22:17:30 UTC 2021
PRIMARY
WIKIPEDIA
AGOMELATINE
Created by admin on Fri Jun 25 22:17:30 UTC 2021 , Edited by admin on Fri Jun 25 22:17:30 UTC 2021
PRIMARY
DRUG BANK
DB06594
Created by admin on Fri Jun 25 22:17:30 UTC 2021 , Edited by admin on Fri Jun 25 22:17:30 UTC 2021
PRIMARY
EVMPD
SUB05286MIG
Created by admin on Fri Jun 25 22:17:30 UTC 2021 , Edited by admin on Fri Jun 25 22:17:30 UTC 2021
PRIMARY
ChEMBL
CHEMBL10878
Created by admin on Fri Jun 25 22:17:30 UTC 2021 , Edited by admin on Fri Jun 25 22:17:30 UTC 2021
PRIMARY
CAS
138112-76-2
Created by admin on Fri Jun 25 22:17:30 UTC 2021 , Edited by admin on Fri Jun 25 22:17:30 UTC 2021
PRIMARY
PUBCHEM
82148
Created by admin on Fri Jun 25 22:17:30 UTC 2021 , Edited by admin on Fri Jun 25 22:17:30 UTC 2021
PRIMARY
INN
7392
Created by admin on Fri Jun 25 22:17:30 UTC 2021 , Edited by admin on Fri Jun 25 22:17:30 UTC 2021
PRIMARY
MERCK INDEX
M1453
Created by admin on Fri Jun 25 22:17:30 UTC 2021 , Edited by admin on Fri Jun 25 22:17:30 UTC 2021
PRIMARY Merck Index
EPA CompTox
138112-76-2
Created by admin on Fri Jun 25 22:17:30 UTC 2021 , Edited by admin on Fri Jun 25 22:17:30 UTC 2021
PRIMARY
IUPHAR
198
Created by admin on Fri Jun 25 22:17:30 UTC 2021 , Edited by admin on Fri Jun 25 22:17:30 UTC 2021
PRIMARY
Related Record Type Details
5-HYDROXYTRYPTAMINE RECEPTOR 2C
TARGET -> INHIBITOR
Structure of AGOMELATINE UREA
SALT/SOLVATE -> PARENT
MELATONIN MT2 RECEPTOR
TARGET -> AGONIST
Ki
MELATONIN MT1 RECEPTOR
TARGET -> AGONIST
AGONIST
Ki
5-HYDROXYTRYPTAMINE RECEPTOR 2B
TARGET -> INHIBITOR
Structure of AGOMELATINE CITRIC ACID
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of AGOMELATINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966